News

In the presence of the President of the Republic, Emmanuel Macron, Sanofi inaugurated today in Neuville-sur-Saône (Rhône-Alpes) a new revolutionary production unit, called "Modulus", to produce its next vaccines and biological drugs.

Somite Therapeutics, a tech-bio company harnessing big data and AI to pioneer novel cell replacement therapies, and OmniaBio Inc., a technology-driven cell and gene therapy CDMO founded by CCRM, today announced a cell therapy development and manufacturing

WellSync, a leader in telehealth innovation, is excited to announce a collaboration with Marius Pharmaceuticals to offer KYZATREX® CIII capsules, an oral form of testosterone replacement therapy on WellSync's comprehensive virtual care platform.

Diamyd Medical will pursue an accelerated approval pathway in the U.S. for its antigen-specific immunotherapy, Diamyd® (rhGAD65/alum), aimed at preserving endogenous insulin production in patients with Stage 3 Type 1 Diabetes. An earlier interim study readout from the ongoing Phase 3 trial, DIAGNODE-3, is planned to serve as the basis

Moderna, Inc. today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization for an updated formulation of the COVID-19 mRNA vaccine Spikevax

Evotec SE and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused on accelerating early-stage drug discovery. 

Innovent Biologics, Inc.a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration

Genprex, Inc.a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its intention to transfer the Company’s diabetes clinical development program and its diabetes gene therapy assets into a new, wholly-owned subsidiary

Merck known as MSD outside of the United States and Canada, today announced that the European Commission (EC) has approved KEYTRUDA ® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv), an antibody-drug conjugate,

Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that the investigational new drug (IND) application of SIM0508